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Abstract
Background: The present health economic evaluation in Afghanistan aims to support public health decision
makers and health care managers to allocate resources efficiently to appropriate treatments for cutaneous
leishmaniasis (CL) elicited by Leishmania tropica or Leishmania major.
Methods: A decision tree was used to analyse the cost and the effectiveness of two wound care regimens
versus intra-lesional antimony in CL patients in Afghanistan. Costs were collected from a societal perspective.
Effectiveness was measured in wound free days. The incremental cost-effectiveness ratio (ICER) and incremental net
monetary benefit (NMB) were calculated. The model was parameterized with baseline parameters, sensitivity ranges,
and parameter distributions. Finally, the model was simulated and results were evaluated with deterministic and
probability sensitivity analyses. Final outcomes were the efficiency of the regimens and a budget impact analysis in the
context of Afghanistan.
Results: Average costs per patients were US$ 11 (SE = 0.016) (Group I: Intra-dermal Sodium Stibogluconate [IL SSG]),
US$ 16 (SE = 7.58) (Group II: Electro-thermo-debridement [ETD] + Moist wound treatment [MWT]) and US$ 25 (SE = 0.48)
(Group III: MWT) in patients with a single chronic CL ulcer. From a societal perspective the budget impact
analysis shows that the regimens’ drug costs are lower than indirect disease cost. Average effectiveness in
wound free days are 177 (SE = 0.36) in Group II, 147 (SE = 0.33) in Group III, and 129 (SE = 0.27) in Group I.
The ICER of Group II versus Group I was US$ 0.09 and Group III versus Group I US$ 0.77, which is very cost-
effective with a willingness-to-pay threshold of US$ 2 per wound free day. Within a Monte-Carlo probabilistic
sensitivity analysis Group II was cost-effective in 80% of the cases starting at a willingness-to-pay of 80 cent
per wound free day.
Conclusions: Group II provided the most cost-effective treatment. The non-treatment alternative is not an
option in the management of chronic CL ulcers. MWT of Group III should at least be practiced. The cost-
effectiveness of Group III depends on the number of dressings necessary until complete wound closure.
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What is already known about the topic?
For nearly a century Sodium Stibogluconate (SSG) has
worldwide been the mainstay treatment in cutaneous
leishmaniasis (CL), especially in Afghanistan. CL chronic
lesions are assumed to be self-healing [1, 2]. Therefore,
the World Health Organization (WHO) CL case man-
agement guidelines rightly promote simple aseptic moist
wound care in the first place and subsequently intra-
dermal Sodium Stibogluconate (IL SSG) injections, in
case CL lesions become chronic [3, 4].
What does this paper add to existing knowledge?
To our knowledge the paper is the first published health
economic investigation on wound care in chronic CL ul-
cers. The analysis shows that simple wound debridement
and moist wound treatment is an efficient treatment al-
ternative to intra-dermal sodium stibogluconate in CL
ulcers in 80% of the cases. Results are based on direct
medical, direct non-medical, indirect costs and efficacy
data collected within a published randomized clinical
trial. Direct non-medical cost and indirect costs have the
most important share in total average patient costs. In-
direct and direct non-medical costs have so far been
neglected in the health economic analysis of wound care
in chronic wounds. Decreasing treatment compliance
and/or efficacy due to parasitic resistance negatively
affect the comparative efficacy of the standard IL SSG
regimen compared to MWT. The non-treatment alter-
native is not an option in the management of chronic
CL ulcers, due to the indirect cost.
(Optional) What insights does this paper provide
for informing health care-related decision
making?
The health economic analyses of the clinical results
show that the proposed MWT is a cost-effective treat-
ment in CL ulcers with or without prior wound debride-
ment using high frequency electro-thermo-debridement
(HF ETD). Methodologically, health economic research
in CL should systematically consider quantifying indirect
cost, the cost-of-illness associated with the disease and
additionally account for patients’ heterogeneity. Models
should be adapted to the regional health care settings so
as to support national health care decision-making.
Remark from the first-author
The magistral DAC N-055 formulation as contained in the
German Drug Codex (DAC) dated of the year 2014 can be
requested from the corresponding author, as well as the
original TreeAge file with the decision analytical health
economic model and the ethical clearances and approvals.
Multilingual abstract
Please see Additional file 1 for translations of the ab-
stract into the five official working languages of the
United Nations.
Background
There is currently no vaccine available to prevent from
scars and disfirgurement due to Old World Cutaneous
Leishmaniasis (OWCL). Although not lethal, cutaneous
leishmaniasis (CL) is treated in order to reduce infec-
tions and increase hygiene in crusted ulcers with bio-
films, to kill the parasite, to reduce scarring, especially in
the face, by accelerating wound healing and to prevent
relapses.
Since the discovery of the less toxic pentavalent anti-
monials in the late 1920s that led to the synthesis of
sodium stibogluconate in 1945 and soon thereafter of
meglumine antimoniate, no comparable drugs against
CL have been discovered and developed.
Afghanistan has the highest incidence of CL caused by
L. tropica or L. major in the world. Around 113 100 to
226 280 cases are estimated in Afghanistan each year [5,
6] and 4000 cases in the Leishmania and Malaria Centre
in Mazar-e-Sharif alone [7, 8].
The economic impact of sodium stibogluconate (SSG)
treatment [9–11] and drug related side effects of SSG
treatment [12] lead to compliance failure, which in turn
increase drug resistance [13]. In fact, the painful admin-
istration, especially for children, lead to patients drop
out of around 59% to 37%, as was reported in clinical
trials [14]. Compliance failures are supposedly much
higher in non-experimental health care settings. Recent
findings indicate genetic drug resistance to SSG in L.
infantum parasites [13, 15].
Because of the disadvantages of a chemotherapeutic
approach to CL cure, physical treatment procedures
have also been studied in the literature [16]: thermother-
apy, cryotherapy, surgery, electrotherapy, laser therapy,
and photodynamic therapy. Although based on a para-
sitic aetiology, CL ulcers are open for more than 8 weeks
and are therefore categorized as chronic [17]. Chronicity
of CL wounds is due to a deficiency of the human im-
mune system to cope with the parasites and to re-
establish the natural wound healing process [18].
A phase IIa double-blind randomized controlled trial
from 2002 to 2008 at the German Medical Service clinic
in Kabul with L. tropica patients has shown that one ap-
plication of bi-polar high-frequency electro-thermo-
debridement (HF ETD) of the lesion under local
anesthesia is an effective method leading to complete
elimination of the parasite load in the scar after primary
healing in 60% of the cases [19]. Moreover, the mean
days for primary wound closure after start of treatment
obtained in the phase IIa trial in Kabul was 42.6 (SD ±
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2.87) days and shorter than the median time of 75 days
for intra-dermal Sodium Stibogluconate (IL SSG) in a
trial conducted by Reithinger et al. in Kabul [14].
On the basis of the above clinical results, a direct com-
parison between HF ETD with subsequent moist wound
treatment (MWT) with DAC N-055 versus IL SSG
within one single trial was considered necessary as a
basis for further evidence-based decision-making. The
Cochrane meta-analysis of González et al. [20] found no
randomized controlled trials (RCTs) on the use of
wound healing to treat OWCL. This led to the introduc-
tion of MWT with DAC N-055 alone as a third regimen
in the Phase IIb RCT, without any previous physical de-
bridement treatment [3].
The objective of the present investigation was to
evaluate the efficiency of wound debridement and MWT
regimens in direct comparison to mainstay IL SSG injec-
tions in CL patients in a mixed population of L. tropica
and L. major parasite species in Afghanistan.
In a first step, a phase IIb RCT was designed and con-
ducted to evaluate the efficacy of the investigated
interventions compared to IL SSG. The clinical results
have been published in Stahl et al. [3]. In summary, 87
patients were enrolled in the trial and were randomized
into group I (n = 24), II (n = 32) and III (n = 31). The PP
analysis of 69 (79%) patients revealed complete epithelia-
lisation before day 75 in 15 of 23 (65%) patients of
Group I, in 23 of 23 (100%) patients of Group II, and in
20 of 23 (87%) patients of Group III (P = 0.004, Fisher’s
Exact Test). In the PP analysis, wound closure times
were significantly different between all regimens in a
pair-wise comparison (P = 0.000039, Log-Rank [Mantel-
Cox] test). Re-ulcerations in patients of Group I, II or III
respectively were not statistically significantly different
(P = 0.312, Pearson Chi-Square Test). The clinical results
are the basis for the efficacy model parameters of the
present cost-effectiveness analysis as detailed in
Additional file 3: Table S2.
In a second step, resources used were identified, quan-
tified and valued on a patient level for all three regimens
parallel to the evaluation of the clinical outcomes, com-
pared in an incremental analysis. Sensitivity analyses
were conducted to investigate robustness of results to
parameter variations. A budget impact analysis was con-
ducted in order to assess the impact in terms of cost of
the alternative regimen from a societal perspective in the
context of Afghanistan.
Methods
Ethical clearance
Ethical clearance of the health economic evaluation was
obtained by the Ethical Committee of the Medical
Faculty of the University of Heidelberg, Germany (S-
318/2009, 18th November 2009) and the International
Review Board at the Ministry of Public Health in Kabul,
Afghanistan (23rd January 2010). The trial was regis-
tered online at Clinicaltrials.gov (ID: NCT00996463,
15th October 2009). All data used was anonymous.
Ethical clearance was obtained from the IRB at the
Ministry of Public Health that the informed consent
could be obtained orally (low literacy rates) and docu-
mented in the electronic case report form. The German
Federal Ministry of Education and Research sponsored
the trial (Grant N° AFG 08/002).
Target population and subgroup
The target population was defined by the patients’ inclu-
sion and exclusion criteria detailed in the clinical and
health economic trial protocol published by Stahl et al.
[3]. All patients were used to parameterize the health
economic analytical model. Subgroup analysis was not
performed due to the small sample size of the under-
lying RCT.
Setting and location
The health economic evaluation was based on cost and
efficacy data on patient level collected during the RCT
conducted at the Leishmaniasis and Malaria Centre
(LMC) in Mazar-e-Sharif, Afghanistan, part of the Pro-
vincial Civil Balkh Hospital complex located in the city
centre. L. tropica and L. major are the two Leishmania
parasite species endemic in Mazar-e-Sharif, located in
the northern Balkh Province of Afghanistan.
Study perspective
The health economic study takes the societal perspec-
tive, including direct medical cost, direct non-medical
and indirect cost. CL treatments are also routinely per-
formed in villages, in environments with very basic
health care facilities, if any. The identification of treat-
ment resources in treatment Groups I to III was there-
fore limited to the most necessary items. This was done
to avoid an over-estimation of treatment resources
needed in the context of one of the poorest country in
the world.
Comparators
Based on the randomization, the CL lesion of the pa-
tients was treated either by IL SSG injection (Group I),
by wound debridement with HF ETD with subsequent
MWT with DAC N-055 (Group II) or by MWT alone
with DAC N-055 (Group III).
Visit protocol
Patients of all three regimens were scheduled to come to
the LMC on a daily basis (with the exception of Fridays)
during the first week of the treatment, followed by visits
to the LMC twice a week until the end of week 4 and
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thereafter once a week until wound closure. Their scars
were checked post closure once a month until 6 months
had passed after the treatment was started.
Treatment protocol
For patients in Group I, 0.6 ml (60 mg) SSG (Albert
David Ltd., India) was administered 12 times by intra-
dermal injections based on a protocol defined by Zeglin
[21], differing from WHO IL SSG standard treatment
protocol [17]. For patients in Group II, the intact skin
surrounding the lesion was cleaned and disinfected.
Following local anaesthesia, the wounds were debrided
with HF-ETD. Subsequently, the wounds were dressed
with jelly containing DAC N-055 (See Formula I in
Stahl et al. [3]). Wound dressings were replaced daily.
From the week 2 onwards patients were treated with
the EuRho® DAC 2003 cream (Euro OTC Pharma
GmbH, Bönen, Germany) until wound closure (See
cream Formula II in Stahl et al. [3]). For patients in
Group III, MWT was performed with DAC N-055
mixed into EuRho® DAC 2003 cream (See Formula II in
Stahl et al. [3]). In the first week, dressing changes were
performed during visits to the LMC in Groups II and
III. Patients and their relatives were trained to change
the wound dressings. Patients received 20 g EuRho®
DAC 2003 cream containing DAC N-055 in a sterile
syringe. During the visits at the LMC, the wound dress-
ings and the healing progress were documented and re-
corded with digital pictures.
Time horizon
CL caused by L. major or L. tropica is supposed to be a
self-healing disease within the first year [1]. Resources
used were documented only during treatment and
follow-up visits within the Phase IIb RCT. It was as-
sumed that no costs were associated with the epithelized
lesion after final wound closure, since patients tend to
be immune against re-infections [22].
Discount rate
No discount rate neither on costs nor effects was applied
due to the time horizon of 1 year.
Choice of health outcomes
Although health related quality of life and cosmetic results
of medical interventions are important in chronic CL le-
sions, days until wound closure are the most essential effi-
cacy outcome for interventions in CL patients [23]. In the
present health economic evaluation, health outcome was
measured in wound free days (WFD), assuming that CL is
a self-healing disease within 303 days. The duration of the
non-treated open lesion was calculated based on literature
[1] and a triangular distribution assumption. Ulcer free
days were calculated as the difference in days between the
self-healing time of CL lesions and the days for wound
closure. In a previous study Stahl et al. [3] measured days
for primary closure as the time in days starting with the
first treatment administration until the day of primary
closure documented with a digital picture. Days for wound
closure were calculated as the sum of days for primary
closure and in case of occurrence, the re-ulceration time
in days.
Measurement of effectiveness
The decision analytical model measures effectiveness as
final wound closure time in days after eventual re-
ulceration [2]. The follow-up period of up to 6 months
also identified patients with re-ulcerations and no final
closure, but without statistical significant difference be-
tween the regimens [3].
The Phase IIb RCT in Mazar [3] was designed as a
mono-centric, controlled, randomized (1:1:1), open label
and phase IIb health economic trial, collecting data on the
clinical efficacy and resources used. For ethical reasons,
the two-stage adaptive drop-loser sample size calculation
was based solely on clinical endpoints. The results of the
Phase IIb RCT [3] confirmed data from the Phase IIa
RCT in Kabul [19] based on a sample size of more than
100 CL patients. There is enough evidence that the single
efficacy and health economic study is a sufficient source
of clinical effectiveness data, despite the small sample size
of 23 patients in each arm. Final outcome of interest in
the health economic evaluation is the incremental cost-
effectiveness ratio of the two proposed regimen compared
to the mainstay treatment with SSG.
Estimating resources and costs
Direct medical resources used in each regimen were
identified and quantified by the pre-defined clinical trial
protocol and complemented by expert interviews by the
local investigators. Valuation of the used items was con-
ducted by averaging local market pharmacy prices. Dir-
ect medical costs were limited to the most necessary
disposable items to administer the respective regimen.
Equipment, furniture, room and personnel costs were
not relevant in the incremental analysis. The identifica-
tion of direct non-medical resources used was limited to
time costs for the patient to reach the treatment centre
and receive treatment. Indirect costs were assumed to
be relevant. CL chronic wounds cause a decrease in
productivity due to the open lesion. The quantification
of the productivity decrease is an estimation based on an
educated guess.
First we calculated the unit cost of each item by
identifying, quantifying and then valuating each item
used per injection or dressing. Thereby the average
cost per dressing and the total dressing costs were
calculated. Finally by adding fixed attributable costs
Stahl et al. Infectious Diseases of Poverty  (2018) 7:12 Page 4 of 16
per patient, we calculated the average cost per pa-
tient. In both regimens, Group II and Group III,
wound dressings were administrated until primary
wound closure. HF ETD was applied only once for
each patient of Group II at the first day treatment
start. In Group II and Group III, the dressings were
changed during each visit and patients were taught to
change their dressings by themselves at home. The
average number of days between two dressings until
wound closure was 3. Depending on the wound clos-
ure time, we could then calculate the total number of
dressings and thereby based on average costs per
dressing, we obtained the average total wound dress-
ing costs for each patient. Direct medical cost of
Group I followed a pre-defined treatment protocol as
described by Stahl et al. [3].
Direct non-medical costs, e.g. travelling expenses,
travelling time, waiting and treatment time, were re-
corded at each patient visit. Time costs were valued
on the basis of 2013 per capita income in
Afghanistan. Depending on the number of visits for
each patient and the average non-medical costs for
each visit, we could calculate the total average non-
medical costs for each patient for each treatment
option.
Indirect costs were calculated according to the human
capital approach on the basis of the average 2013 per
capita income in Afghanistan multiplied by the days ne-
cessary for primary closure of the lesion. After wound
closure productivity loses were assumed to equal zero.
All costs were calculated without value-added taxes,
which are not existent in Afghanistan.
Currency, price data, and conversion
Resource quantities of direct medical costs were cal-
culated on the basis of the clinical trial protocol and
collected alongside the trial between 2009 and 2011.
Direct non-medical resources used were documented
during the entire trial period between 2009 and 2011
for each patient. The productivity loss, that is indirect
medical resources used, was estimated. Quantities
were valued on the basis of Afghanis and if applicable
German prices in 2013. Afghanis (Afs) and Euros (€)
were converted to American Dollars (US$) with the
average exchange rates of 2013 of the respective cen-
tral banks. To update resources valued in monetary
terms to a respective year subsequent to 2013 or
make cost comparable to cost of other publications,
present costs valued in US$ of for year 2013 need to
be adjusted for inflation up to the year of interest,
converted into local currency with the current
exchange rate and converted into purchasing power
parities of the respective year.
Choice of model
Although a simple 3-stage Markov model describing the
wound healing process of chronic wounds [24] would
have been an attractive framework for the health
economic evaluation of the study, the RCT did not in-
clude pre-defined recurrent health states. The decision
problem involves a continuous risk over time of primary
epithelisation and re-ulceration until final lesion closure.
Timing of the lesion closure is an important characteris-
tic of the chronic wound healing process as well.
However, in the observation period of up to 180 days
the RCT, re-ulceration only happened once. Therefore,
instead of a Markov model, a decision analytical model
was used to describe the health states identified during
the clinical trial and formalized in a decision tree model
[25].
Model assumptions
One central assumption of the health economic model is
that the disease is self-healing [1] and not lethal. In case
of non-compliance or unsuccessful treatment, the self-
healing time of the chronic CL lesion did not alter. As-
sumption over resource consumption in non-compliant
patients was estimated as an educated guess fraction of
average resources used for primary closure. Percentage
productivity loss had to be estimated with an educated
guess and assumed equal in all three regimen. Finally,
the health economic model did not account for costs of
side effects or complications such as infections due to
the health care provision or the administrated treat-
ments. In case of parasitic resistance to IL SSG or ulcers
with no final closure after re-ulceration, the maximum
number of injections and the SSG dosage was not in-
creased. In contrast, in Group II and III DAC N-055
MWT dressings were administered until final closure of
the CL ulcer. Patients were not re-assigned to another
regimen in case of resistance or wound closure failure
before self-closure of the CL lesion. Concerning the
number of lesions per patient and the rate of productivity
loss, no probabilistic distribution was defined due to
lacking clinical evidence. The model needs to assume
simultaneous wound closure, if simulated with more than
one lesion. There are missing socio-economic investiga-
tions of indirect costs in chronic CL ulcers [26, 27].
Study parameters
The baseline study parameters, the sensitivity ranges,
and the distribution used in the decision tree are de-
tailed in Additional file 3. Additional file 3: Table S1
contains the parameters used to calibrate the decision
nodes. Additional file 3: Table S2 detail the efficacy
parameters. Additional file 3: Tables S3-S5 detail the
direct medical, the direct non-medical and the indirect
cost of the three regimens.
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The baseline nodes probabilities for all three regi-
mens were based on the patient data from Stahl et al.
[3]. Sensitivity ranges were defined as ±10% deviations
from baseline values. In the probabilistic sensitivity
analysis, the parameters of the beta distributions are
defined according to the number of patients in the
clinical trial in the respective pre-defined and photo-
documented health states.
The efficacy parameter of the regimens result from
the RCT [3]. Sensitivity ranges were defined in most
cases with obtained minimum and maximum values.
The small sample size restricted the use of confidence
intervals to the sensitivity ranges of mean days for
primary closure parameters and constituted the ra-
tionale for using the triangular distribution within
probabilistic analyses. The triangular distribution pa-
rameters were based on the respective minimum and
maximum sensitivity ranges of each parameter. The
modus of the triangular distribution was chosen such
that the baseline parameter value resulted as mean
from the parameterized triangular distribution.
Within the direct medical cost, the baseline unit
price of 8.5 cent per gram for the preparation of the
magistral DAC N-055 basic crème preparation ac-
cording to the formula detailed in Stahl et al. [3] was
solely based on the tax-exempted wholesale prices of
the ingredients. The DAC N-055 jelly price equals
that of the basic crème (see Stahl et al. [3] for DAC
N-055 basic crème formula). Sensitivity ranges were
defined as plausible minimum and maximum unit
price values for 2013. The final price depends on the
additional cost for the DAC N-055 basic crème prep-
aration in pharmacies or companies with good manu-
facturing production (GMP) license and all additional
cost associated with commercialization. Probabilistic
sensitivity analyses were conducted on the basis of a
gamma distribution around the baseline DAC N-055
basic crème price. Data to quantify direct non-
medical cost of CL treatments were collected at each
patient visit during the RCT. Parameters represent
average values. Baseline indirect cost, e.g. productivity
losses due to the disease, was assumed to average 1%
reduction of labor productivity until wound closure.
Since after CL infections women might not be
allowed to cook, to have children or to marry in
Afghanistan [27], the indirect cost of CL ulcers and
especially the indirect cost of persisting CL scars
were underestimated in the present health economic
evaluation. For women in Afghanistan, marriage is
still the main income security. Nonetheless, the sensi-
tivity range was conservatively defined to vary from 1
to 20% to account for comparability with variations
of other variable values within the tornado diagram
analyses.
Analytic methods
The decision tree was calibrated based on probabil-
ities of health states within the RCT, which are the
compliance, primary closure, re-ulceration and final
closure after re-ulceration. Four different final health
states were modeled and defined according to their
costs and efficacy outcome. The decision tree is rep-
resented in Additional file 4. The health economic
model was simulated with TreeAge Pro 2014 (Tree-
Age Software, Inc., One Bank Street, Williamstown,
MA 01267, USA) with the parameter values reported
in Additional file 2. Study baseline parameters were
calculated on the basis of the RCT primary patient
level data collected [3]. Sensitivity ranges were calcu-
lated on the basis of minimum, maximum values,
confidence intervals or ±10% deviations. Minimum,
maximum values were taken for parameters with
small samples. Resource prices were assumed to vary
up to ±10%. Confidence intervals were calculated for
efficacy data. Distributions were defined for the dif-
ferent parameters according to the data properties.
Costs were typically left skewed distributed and
followed a gamma distribution. Data defined by their
minimum, maximum and modus properties followed
a triangular distribution. Decision paths probabilities
calculated on the basis of the fraction of patients
within that health state were calibrated according to
the beta distribution. All other parameters were de-
fined as normally distributed [28]. According to
WHO-CHOICE criteria [10] a health intervention is
very cost-effective if the incremental cost-
effectiveness ratio (ICER) is below the respective per
capita gross domestic product (GDP), cost-effective if
between one to 3 times the per capita GDP of a
country, and not cost-effective if above 3 times the
per capita GDP. In Afghanistan, the per capita in-
come per day was around US$ 1.92 in 2013. The in-
cremental cost per incremental WFD of the health
interventions should be below that US$ 1.92 thresh-
old to be very cost-effective. Therefore, the net mon-
etary benefit (NMB) corresponds to the threshold
(WTP) of US$ 1.92 multiplied by the medical out-
come measured in natural units (WFD) minus the
resources used valued in monetary units (Cost). In
this case the threshold is defined as willingness-to-
pay (WTP) per natural outcome and in the present
cases monetarily values a WFD with US$1.92. The
analysis was conducted on the assumption that the
three regimens were mutually exclusive. A baseline
incremental cost-effectiveness analysis, a budget im-
pact analysis, uni- and multivariate sensitivity ana-
lyses, and a probabilistic Monte-Carlo simulation
with 10 000 iterations were conducted with the Tree-
Age software.
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Results
Baseline evaluation
The baseline cost-effectiveness analysis in Fig. 1 corre-
sponds to average treatment costs and WFD for patients
with the baseline patients’ clinical characteristics detailed
above with one CL lesion. The average costs and WFD
values given in Table 1 are weighted by their probability
of occurrence in each pre-defined health state. The
mean costs of US$ 15.91 (SE = 7.58) in Group II and
US$ 24.97 (SE = 0.58) in Group III are higher than the
costs of US$ 11.43 (SE = 0.016) in Group I. Regular
dressing changes to promote the lesion’s closure and
avoid super-infections increase the average cost of treat-
ment in Group II and Group III by US$ 4.48 and US$
13.54 respectively compared to IL SSG injections with
no adjuvant wound care until final closure. Baseline ef-
fectiveness in wound free days are 177 (SE = 0.36) in
Group II, 147 (SE = 0.33) in Group III, and 129 (SE =
0.27) in Group I. Group II versus Group I has the high-
est incremental effectiveness of 48 WFD compared to 17
incremental WFD in Group III versus Group I. The ef-
fectiveness findings are based on the simulation of the
calibrated decision tree. The simulation findings reflect
the results from the underlying clinical RCT [3] and
thereby validate clinically the health economic model
used. When compared to Group I, the ICER of Group II
of US$/WFD 0.09 and US$/WFD 0.77 of Group III are
below an Afghan per capita income threshold of US$
1.92 per day in 2013. In a mutually exclusive compara-
tive cost-effectiveness analysis against Group I, Group II
is more efficient than Group III. Given the resources
used included in the analysis, all three regimen have a
positive net monetary benefit (NMB) as stated in Table 1
assuming a WTP of US$/WFD 1.92 in 2013: US$ 236 (SE
= 0.51) in Group I, US$ 324 (SE = 7.6) in Group II, and
US$ 257 (SE = 0.80) in Group III. Given the baseline par-
ameter, remarkably the total cost share of direct medical
cost is half that of direct non-medical cost per patient.
Half of direct medical costs are drug costs, which roughly
average to US$ 4 in the WHO-EMRO IL SSG protocol
[17] compared to US$ 1.20 in the IL SSG protocol defined
by Zeglin [21] and tested in Stahl et al. [3].
Heterogeneity
Heterogeneity was not simulated in the health economic
model due to the non-significant difference in the
underlying patient population of the Phase IIb RCT [3].
However, the number and size of lesions per patient, the
parasite specie, the patients’ age and gender should be
investigated in future treatment evaluations to
characterize heterogeneity. This was not possible regard-
ing the sample size of the underlying clinical study.
Cost sensitivity
Changes in parameter values show different parameter
sensitivities of costs (see Additional file 4: Figures S1-S6).
Moreover the extent of changes in average total cost
depends also on the ranges of variation of the model
parameters (see Additional file 3). Some parameters only
change in steps of 100% and above to impact average cost,
like for example the number of lesions or the total num-
ber of injections. Obviously, the sensitivity of average costs
in Group I to parameter value variations is less important
than in Group II and III. In Group I, the most sensitive
Fig. 1 Average Cost per Patient by Regimen. Comparison of direct medical, drug, direct non-medical, and indirect cost per patient for each regimen
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Table 1 Cost and effectiveness with baseline parameters
Health states Av. Total
Non-compliant Primary closure No primary closure Final closure No final closure
Probability of health
states
WHO EMRO protocola 0.39 0.48 0.03 0.08 0.03 1.00
Group I 0.39 0.48 0.03 0.08 0.03 1.00
Group II 0.28 0.62 0.01 0.06 0.03 1.00
Group III 0.26 0.51 0.01 0.06 0.16 1.00
Direct medical
cost
Group I (US$) 0.87 3.48 3.48 4.93 4.93 2.63
Group II (US$) 0.81 3.26 28.31 6.26 23.40 3.58
Group III (US$) 1.05 4.21 28.14 8.02 24.53 7.09
Injections/dressings
WHO EMROa (N =) 2 8 8 13 13 6
Group I (N =) 3 12 12 17 17 9
Group II (N =) 3 11 101 21 72 12
Group III (N =) 4 15 101 28 73 23
Drug cost
WHO EMROa (US$) 1.32 5.28 5.28 8.58 8.58 4.11
Group I (US$) 0.40 1.58 1.58 2.24 2.24 1.20
Group II (US$) 0.47 1.87 17.17 3.57 12.24 2.03
Group III (US$) 0.64 2.55 17.17 4.76 12.41 3.90
Direct non-medical
cost
Group I (US$) 1.36 7.70 7.70 9.97 9.97 5.50
Group II (US$) 1.88 10.26 69.22 17.57 49.59 10.05
Group III (US$) 2.23 11.29 60.12 19.35 43.47 15.02
Indirect cost
Group I (US$) 5.82 1.32 5.82 1.61 5.29 3.31
Group II (US$) 5.82 0.63 5.82 1.64 4.80 2.32
Group III (US$) 5.82 0.86 5.82 1.61 5.07 2.90
Total average cost
Group I (US$) 8.05 12.50 17.00 16.51 20.19 11.43
Group II (US$) 8.51 14.15 103.35 25.47 77.79 15.91
Group III (US$) 9.10 16.36 94.08 28.98 73.07 24.97
Wound free days
Group I (WFD) 0 234 0 207 0 129
Group II (WFD) 0 270 0 167 0 177
Group III (WFD) 0 258 0 233 0 147
ICER
Group I (US$/WFD) N.A. 0.00 N.A. 0.00 N.A. 0.00
Group II (US$/WFD) N.A. 0.05 N.A. −0.22 N.A. 0.09
Group III (US$/WFD) N.A. 0.16 N.A. 0.48 N.A. 0.77
NMB (WTP = 1.92)
Group I (US$) −8 437 −17 381 −20 236
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cost parameters are the number of lesion, the SSG unit
price, and the duration of the natural wound healing, in
Group II and III the DAC N-055 unit price, the number of
lesions, and the average days between two dressings, and
additionally in Group II the probability of primary closure.
Drug price
Figure 2 shows the comparative patient costs of the three
regimens as a function of DAC N-055 and SSG unit drug
price with an average IL SSG dosage of 2.75 ml per injec-
tion per lesion for an average number of 9 injections
according to the WHO EMRO case management guide-
line [4]. In our model, average patients’ cost in Group III
(red color) will always be higher than average patients’ cost
in Group II or III, independently of price variations in
either drug. However, patients’ costs in Group II (blue sur-
face) are lower than in Group I (brown surface) depending
on the price relation between SSG and DAC N-055.
Sensitivity of direct non-medical cost
Independently of the regimen, the frequency of visits, in-
cluding follow-up visits, increases average cost by US$ 3 to
10. The share of direct non-medical costs can be 24 to 67%
of total average costs. Table 3 shows that the cost variations
are small in Group I, but a reduction of the number of
visits in Group II or III from 12 to 6, impacts the INMB of
the wound care regimens compared to IL SSG by US$ 3 to
4 per patient, which corresponds approximately to average
SSG drug cost per patient according to the WHO EMRO
protocol [4].
Sensitivity of indirect cost
Loss of productivity, defined as indirect costs, is calcu-
lated in the simple decision analytical model with the
time the CL ulcers is either open or re-ulcerated until
final closure. Table 3 shows the effect of differences in
the percentage of productivity loss on the choice of the
dominant cost-effective regimen. A productivity de-
crease from 1 to 10% has approximately the same abso-
lute impact on average patient cost of Group II and III
as a unit price increase of DAC N-055 basic crème by
around 1000% (See Table 3 and Additional file 4:
Figures S2 and S3). In case productivity loss solely in
Group I increased from 1 to 10%, both alternatives of
Group II and III would dominate the treatment strategy
of Group I. Accurate quantification on the impact of
chronic wounds on productivity and income, especially
for women in case of CL, even after wound closure, are
Table 1 Cost and effectiveness with baseline parameters (Continued)
Health states Av. Total
Non-compliant Primary closure No primary closure Final closure No final closure
Group II (US$) −9 504 − 103 295 − 78 324
Group III (US$) −9 479 −94 418 −73 257
All costs in 2013 US$
a WHO EMRO protocol is defined as 1 to 5 ml IL SSG, twice weekly for three to 4 weeks [4]. The probability of health states of Group I was also assumed for the IL
SSG WHO EMRO protocol, as a best guess. We assumed a mean IL SSG dosage of 3 ml per injection and 5 additional injections for final closure based on the IL
SSG re-ulceration time found in Stahl et al. [3]
Fig. 2 Three-way Sensitivity Analysis of Drug Pricing. Variations of unit drug price of DAC N-055 basic crème or jelly and SSG with an average
2.75 ml dosage of SSG per lesion according to WHO-EMRO case management guidelines [19]
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sparse as our yet unpublished systematic literature
review has shown [26].
Budget impact analysis
The budget impact analysis of Table 2 considers the add-
itional resources needed to provide the proposed treat-
ments, without quantifying or valuing the effectiveness
of the regimens. The baseline budget impact analysis
was calculated for Afghanistan on the basis of the esti-
mated CL incidence data published by Alvar et al. [5].
The budget impact analysis has the limitation to con-
sider CL patients with only one lesion, due to the evi-
dence collected within the underlying RCT [3]. Based on
average incidence, comparison of Group II and III to
Group I result in additional societal cost of around US$
0.765 and 2.301 million respectively. In case of non-
Table 2 Budget impact analyses with baseline parameters
Number of patients (N)a
WHO EMRO protocol Group I Group II Group III
Health states
Non-Compliant 65 500 65 500 47 683 43 780
Primary closure 81 621 81 621 104 868 86 712
No primary closure 4582 4582 1358 1358
Final closure 13 575 13 575 10 521 10 860
No final closure 4582 4582 5260 27 150
Budget impact (US$ 2013)a
No treatment Group I Group II Group III
Health states
Non-Compliant – 527 278 405 781 398 398
Primary closure – 1 020 261 1 483 888 1 418 602
No primary closure – 77 888 140 300 127 715
Final closure – 224 127 268 069 314 727
No final closure – 92 503 409 206 1 983 880
Total
Av. incidence (169 860 cases) 879 875 1 942 056 2 707 244 4 243 322
Min. incidence (113 100 cases) 585 858 1 294 399 1 804 404 2 828 215
Max. incidence (226 280 cases) 1 172 130 2 589 714 3 610 085 5 658 430
NMLCP rep. Incidence (22 620 cases) 117 172 258 880 360 881 565 643
Drug cost (US$ 2013)a
WHO EMRO protocol Group I Group II Group III
Health states
Non-Compliant 86 460 25 938 22 292 27 910
Primary closure 430 958 129 287 196 104 221 115
No primary closure 24 191 7257 23 309 23 309
Final closure 116 475 30 463 37 559 51 694
No final closure 39 310 10 281 64 387 336 936
Total
Av. incidence (169 860 cases) 697 395 203 227 343 650 660 963
Min. incidence (113 100 cases) 464 821 135 453 229 046 440 538
Max. incidence (226 280 cases) 929 970 271 001 458 254 881 388
NMLCP rep. Incidence (22 620 cases) 92 964 27 091 45 809 88 107
a The budget impact calculations for the average estimated incidence differentiated by health states is calculated with the total average cost per patient with one
lesion and the drug cost for each regimen. Drug costs represent solely the costs of SSG and DAC N-055 basic crème according to the pre-defined dosage and
posology. The number of patients are based on estimated average incidence published by Alvar et al. [5] and the probability of final health states used in the
present decision tree model. In case “no treatment” is administered, based on Afghan 2013 per capita income of US$ 700 and an average lesion duration of
303 days, according to our simple model and the educated guess, indirect cost due to one CL lesion amount to US$ 5.81. If additionally, productivity loss due to
CL exceeds 1% of daily income, the societal budget impact of “no treatment” is considerable
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treatment, direct resources are not used, but economic
relevant indirect costs still have to be considered. The
budget impact of the no-treatment alternative is US$
879 875, which is higher than the drug cost of the
WHO-EMRO guideline IL SSG regimen in Group I
of US$ 697 395, and higher than the drug cost of
US$ 343 650 in Group II and US$ 660 963 in Group
III. When indirect costs are considered, the “no
treatment” alternative is no sustainable option. This
result can be confirmed in a NMB calculation of the
treatments, when outcome of respective CL treat-
ments are valued in WTP, as detailed in Table 1.
Depending on the number, size, site and severity of CL
ulcers, productivity losses can be assumed to be higher
than 1%, especially for children and women, in case
when life-long stigmatization costs of CL disfiguring
scars are taken into account. To calculate the disability
adjusted life years (DALYs), the disability weight (DW)
for CL used by WHO equals 0.023 or 2.3% per year. The
indirect cost based on the productivity loss of 1% is
therefore an underestimation compared to the CL dis-
ability weight used in DALY calculations.
Outcome sensitivity
Additional file 4: Figures S4-S6 represent the absolute
variations in effectiveness in average WFD based on pre-
defined parameter variations. The most outcome-
sensitive parameters are the duration of the disease, the
probability of treatment compliance, the probability of
primary closure. However, variations in effectiveness of
Group III additionally depend on the probability of re-
ulceration.
Three way-sensitivity analysis
Parasitic resistance and patient compliance due to po-
tential pain and toxic side effects of IL SSG regimen are
the most important parameters to investigate compara-
tive effectiveness of alternative regimens to treat CL as
shown in Additional file 4: Figure S7 and S8. The prob-
ability of primary closure in Group I was interpreted as
proxy for parasitic resistance. Moreover, the SSG regi-
men has side effects that, although very rare, can poten-
tially be fatal (anaphylactic shock and cardio-toxicity),
especially in children and elderly persons, besides the re-
peatedly painful administration. The probability of com-
pliance in SSG regimen can be interpreted as proxy for
the adverse effects of therapy. The 3-way sensitivity ana-
lysis investigates the dominant regimen with respect to
WFD as a function of the probability for primary closure
in Group II versus Group I versus the baseline parame-
ters of Group III in dependence of the probability of
compliance in Group I (12.5% versus 25% non-
compliant patients (Additional file 4: Figures S7 and S8,
respectively)).
At a compliance rate of 75% in Group I and a 100%
primary closure probability in Group I, wound debride-
ment with subsequent wound care in Group II is the
most effective treatment given baseline parameters (blue
surface). Below a probability of primary closure in Group
II of 82 and 89% in Group I, simple MWT shows the
highest effectiveness, given baseline parameters. The
shift in the probability of compliance in Group I from
75 to 87.5% increases the probability of dominance in ef-
fectiveness of Group I (compare brown surface in
Additional file 4: Figures S8 and S7).
Sensitivity of incremental cost-effectiveness ratios
The ICERII,I comparing Group II versus Group I varies
up to US$ 0.47 due to uni-variate unit drug price in-
crease of Group II from US$ 0.085 to 1.0. In Group II,
the probability of primary closure (90 to 100%), the
number of lesions (1 to 4), and the average days between
two dressings (2 to 4 days) impact the most the ICERII,I
variation: US$ 0.23, US$ 0.22, and US$ 0.18,
respectively.
In contrast, the ICERII,I spreads only by US$ 0.05, if
the days for primary closure in Group II change within
the confidence intervals of 29 to 37 days obtained in the
underlying RCT [3]. Variations in the probability of
compliance in Group II as defined in the Additional file 3
within the ±10% sensitivity ranges, affect the ICER by up
to US$ 0.04. All ICERII,I are all below the WTP thresh-
old of US$ 1.92.
The ICERIII,I is sensitive to Group I parameter varia-
tions in the probability of treatment compliance (spread
US$ 2.412), to the absolute days for primary closure
(spread US$ 1.252), and the probability of primary clos-
ure (spread US$ 0.734).
The ICERIII,I is sensitive to Group III probability of
treatment compliance (spread US$ 3.739), Group III
probability of primary closure (spread US$ 3.476), to the
DAC N-055 drug unit price (spread US$ 2.65), and the
number of lesions in Group III (spread US$ 1.207).
Probabilistic sensitivity analysis
Cost-effectiveness plane and acceptability curve
Stochastic uncertainty was explored within a probabilis-
tic sensitivity analysis on the basis of all the defined dis-
tributions and calculated distribution parameter values.
The cost-effectiveness plane of Group II and Group III
versus Group I and Group III versus Group II are repre-
sented in Additional file 4: Figures S9-S11. A Monte-
Carlo simulation with 10 000 iterations allowed calculat-
ing the probability for each intervention to be cost-
effective depending on a willingness-to-pay threshold.
The results are represented graphically in the cost-
effectiveness acceptability curve (CEAC) in Fig. 3. Group
II is the most cost-effective strategy in 80% of the cases
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starting with a WTP of about 80 cents. Group III is only
the most cost-effective strategy in 10% of the cases at a
WTP of 80 cents per WFD. If patients or society does
not value wound free days with a willingness-to-pay,
then the most cost-effective treatment is IL SSG in over
90% of the cases, since the average cost per patient for
Group I is the lowest. The median costs and outcomes
of the Monte-Carlo simulation confirm baseline results.
Discussion
Study findings
Table 1 shows that ETD with MWT is the most cost-
effective treatment compared to standard IL SSG treat-
ment. MWT is the second best treatment alternative
compared to standard IL SSG treatment. The budget im-
pact analysis of Table 2 shows that societal costs of non-
treatment are higher than the drug cost of either treat-
ment. Economic evaluations of treatment alternatives fo-
cusing only on drug or direct medical cost, lead to
misallocation of resources.
On the side of resources used, direct costs and indirect
cost amount only to around one quarter of total cost.
Direct non-medical costs amount to half of baseline
treatment costs. Table 3 shows how strong variation in
the number of visits and in productivity loss impact
average treatment cost. On the side of effectiveness,
probability of compliance, primary closure, and re-
ulceration are the most important effectiveness-sensitive
parameters to monitor during the implementation of the
proposed regimen. The baseline results are robust to dif-
ferent sensitivity analysis.
The present health economic evaluation did not ac-
count for loss in expected “lifetime-income” of potential
serious adverse event cases. The patients’ health risks of
any kind of treatment should not be increased, especially
when the disease is self-healing like CL. The indirect
costs resulting from serious adverse events would prob-
ably additionally advocate against the on-going use of
SSG in specific patient populations.
Limitations
Productivity losses have to be evaluated more accurately,
because the efficient allocation of resources within soci-
ety depends on their quantification. Cost-of-illness
(COI), quantifying the opportunity cost of CL being en-
demic in a country or region, were not accounted for in
the evaluation of the three regimens. COI quantify not
merely the cost of disease management, but the re-
sources used compared to a situation where there is no
disease. Therefore, COI include for example the oppor-
tunity cost of vector and disease surveillance, prepared-
ness and control activities, effects on tourism,
information, communication and education, besides the
cost of social stigmatization, especially for women in
Afghanistan. Treatment regimens can impact COI
differently.
Moreover, the health economic model was based on a
single Phase IIb RCT [3] with a relatively small sample
size and clinical endpoints and patient characteristics in-
volving one single CL lesion. Therefore, the model can-
not account for primary data heterogeneity or subgroup
analysis.
Fig. 3 Cost-Effectiveness Acceptability Curve. Cost-effectiveness acceptability curve resulting from a probabilistic sensitivity analysis with 10 000 iterations
in a Monte Carlo simulation
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Table 3 Sensitivity analysis on the impact of the number of visits at the treatment centre on average cost per patient and on the
impact of productivity loss on average cost per patient
Av. days open
CL ulcer
Av. cost per
patient
Av. direct
non-medical
cost per patient
NMB
(WTP = 1.92)
INMB
(WTP = 1.92)
% of av.
cost
Abs.
value
Group II: 6
visits
Group II: 12
visits
Group III: 6
visits
Group III: 12
visits
Group I
6 visits at treatment
centre
174 10.13 27 2.71 238 90 86 29 25
9 visits at treatment
centre
174 11.43 36 4.07 236 92 88 31 27
12 visits at treatment
centre
174 12.50 43 5.42 235 93 89 32 28
Group IIa
6 visits at treatment
centre
126 11.82 35 4.09 328 0 −4 −61 −65
9 visits at treatment
centre
126 13.87 44 6.14 326 2 −2 −59 −63
12 visits at treatment
centre
126 15.91 51 8.18 324 4 0 −57 −61
23 visits at treatment
centre
126 23.42 67 15.69 316 12 8 − 49 −53
Group IIIa
6 visits at treatment
centre
156 14.88 24 3.56 267 61 57 0 −4
9 visits at treatment
centre
156 16.66 32 5.34 265 63 59 2 −2
12 visits at treatment
centre
156 18.44 39 7.12 263 65 61 4 0
23 visits at treatment
centre
156 24.97 55 13.65 257 71 67 10 6
Av. days open
CL ulcer
Av. cost per
patient
Av. indirect cost
per patient
NMB
(WTP = 1.92)
INMB
(WTP = 1.92)
% of av.
cost
Abs.
value
Group I: 1%
prod. Loss
Group I: 10%
prod. Loss
Group I: 20%
prod. Loss
Group I
1% productivity loss 174 11.43 28.96 3.31 236 – 30 63
10% productivity loss 174 41.19 80.38 33.11 207 −30 – −33
20% productivity loss 174 74.26 89.17 66.22 174 −63 −33 –
Group II
1% productivity loss 126 15.91 14.59 2.32 324 88 118 151
10% productivity loss 126 36.60 62.79 22.98 304 67 97 130
20% productivity loss 126 59.58 77.16 45.97 281 44 74 107
Group III
1% productivity loss 156 24.97 11.62 2.90 257 20 50 83
10% productivity loss 156 51.10 57.73 29.50 231 −6 24 57
20% productivity loss 156 80.12 72.50 58.09 202 −35 −5 28
a No changes have been made to the treatment protocol in each regimen, only the number of visits to the centre have been varied. Dressing changes can be
done by the patient himself, visits at the centre can be reduced to a minimum check of the wound healing process. In Group I, 6 visits correspond to the WHO
protocol, 6 visits to the average of visits including non-compliant patients, and 12 visits to the foreseen RCT protocol for IL SSG injections
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The follow-up period of future trials should be ex-
tended to 365 days to monitor re-ulceration rates and
account for the self-healing assumption of CL within 1
year. Theoretical heterogeneity calculations with respect
to the number of lesions per patient should also guide
future research. Such evaluations should not be based
necessarily on the assumption that the patients’ lesions
close and eventually re-ulcerate simultaneously.
The authors did not find any RCT investigating the ef-
fectiveness of WHO IL SSG in dependence of dosage
and posology. EMRO-WHO IL SSG dosage and posol-
ogy recommendations [4] increase the average drug
costs per CL patient. Moreover, the societal budget im-
pact analysis did not include a probabilistic analysis. The
authors assumptions is that shorter primary wound clos-
ure improves cosmetic outcome, especially of CL ulcers
on the face. Therefore the treatment decision impact the
long term costs of stigmatization, social exclusion of af-
fected women and children [6]. However, the present
model did not include indirect cost due to disfiguring
scarring and the cosmetic outcome of treatment. In the
majority of cases, CL treatment in Afghanistan is fi-
nanced out-of-pocket. Therefore, indirect costs are de-
cisive for the CL patient and relatives. The authors’
assumption of 1% productivity reduction on average is
conservative considering the CL disability weight of
0.023 used in disability adjusted life years (DALYs)
calculations.
Generalizability
The health economic results obtained are applicable to
the context of Afghanistan. The decision tree model can
be calibrated with parameter values corresponding to
the prices of other country settings to investigate the
cost-effectiveness of the proposed interventions, assum-
ing the reproducibility of the clinical results in other
health care settings given the power and significance
level of the sample size calculation in Stahl et al. [3].
The decision tree model was used based on the health
states documented during the RCT. Future CL trials
could document the clinical healing process of chronic
wounds more dynamically by differentiating health states
such as open lesion, debrided wound with or without
tissue granulation with or without infection and bio-
film, lesion closure, re-ulcerations, final closure. The
clinically based health economic models in CL chronic
wounds would need to be adapted accordingly.
The treatment approach of Group II is based on
findings in the healing process of chronic wounds in-
dicating that bio-films are a major source for bacterial
proliferation and super-infections leading to complica-
tions in wound healing and days for complete epithe-
lization [24]. The discussion of the present findings
should be conducted through transparent scientific
health economic evidence without conflict of interest.
Current knowledge
The present economic evaluation of CL wound care
regimen is the first published cost-effectiveness ana-
lysis conducted alongside a clinical trial in CL pa-
tients in Afghanistan. In a systematic literature review
on the health economics of chronic wounds to be
published by Leporowski et al. (Master thesis not yet
published [26]), cost and effectiveness data was ex-
tracted from 66 publications from a total of 732 pub-
lications screened and published since 1966. The
systematic review focused on health technologies for
the treatment of chronic wounds with the highest an-
nual incidence in western countries: venous and arter-
ial ulcers, diabetic foot ulcers, and pressure ulcers.
Leporowski et al. found ten cost-of-illness, five cost-
minimization, 37 cost-effectiveness and 14 cost-utility-
analysis. Although all costs were converted with pur-
chasing power parity to IUS$ 2014 difficulties prevail
to compare interventions with respect to their costs
and effectiveness due to very different methodological
approaches. The results of the systematic literature
review [26] indicate that the resources and the out-
come parameters considered in the present health
economic investigation correspond to best scientific
practices and the results are generate on the best
available evidence.
Conclusions
Jebran [19] showed the rationale of adjuvant applica-
tion of MWT with DAC N-055 in wound care of
chronic CL ulcers compared to simple adjuvant
MWT with physiological saline, especially in CL le-
sions with L. tropica rest load after primary wound
closure. The present health economic evaluation
shows that adjuvant MWT in crusted chronic CL le-
sions covered by bio-films and infiltrated with L. tro-
pica or L. major parasites is an efficient treatment
option in the context of Afghanistan. However, aver-
age costs and effects in Group II have unexplained
higher standard errors compared to Group I and
Group III. The baseline results of adjuvant MWT and
prior electro-thermo-debridement are robust against
probabilistic sensitivity analyses. The comparative ef-
ficiency of Group III depends on the probability of
treatment compliance, the probability of primary
closure, and can be a sustainable efficient alternative
to SSG or complement the IL SSG wound treatment
depending on the clinical case as for instance chil-
dren, women, or elderly. Decision makers should be
aware, when allocating resources, that from a societal
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health economic perspective based on the budget im-
pact analysis, the indirect cost and the NMB baseline
calculations, aseptic MWT should always be offered
to CL patients. Wasted resources are less and med-
ical outcome are better compared to no-treatment of
CL patients.
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